Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Long-Term Debt Repayments (2022)

Historic Long-Term Debt Repayments for Orchestra BioMed Holdings (OBIO) over the last 1 years, with Q2 2022 value amounting to $5.4 million.

  • Orchestra BioMed Holdings' Long-Term Debt Repayments changed N/A to $5.4 million in Q2 2022 from the same period last year, while for Dec 2022 it was $6.4 million, marking a year-over-year change of. This contributed to the annual value of $10.8 million for FY2023, which is 6830.59% up from last year.
  • Orchestra BioMed Holdings' Long-Term Debt Repayments amounted to $5.4 million in Q2 2022.
  • Orchestra BioMed Holdings' Long-Term Debt Repayments' 5-year high stood at $5.4 million during Q2 2022, with a 5-year trough of $1.0 million in Q1 2022.